American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110) and cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Sigma Chemical Co., St. Louis, MO), 10 mM Hepes, pH 7.2, 50 µM 2-ME, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco, Grand Island, NY).--

In the Claims:

Please cancel claims 3, 24-27 and 55-66 without prejudice.

Please amend the claims as follows:

1. (amended) An antisense compound 8 to 30 nucleobases in length which is targeted to a 5'-untranslated region, a coding region, a stop codon region, or a 3'-untranslated region of murine interleukin-5 of SEQ ID NO: 1 or a 5'-untranslated region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule encoding human interleukin-5 of SEQ ID NO: 78, wherein said antisense compound modulates murine or human interleukin-5.

5. (amended) An antisense compound 8 to 30 nucleobases in length which is targeted to a 5'-untranslated region, a start codon region, a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule encoding murine interleukin-5 receptor a of SEQ ID NO: 132, a coding region or a 3'-untranslated

region of a nucleic acid molecule encoding murine interleukin-5 receptor a of SEQ ID NO: 133, or a 5'-untranslated region, a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule encoding human interleukin-5 receptor a of SEQ ID NO: 176, wherein said antisense compound modulates the expression of murine or human interleukin-5 receptor a.

13. (amended) The antisense compound of claim 12 consisting of SEQ ID NO: 209.

21. (amended) A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

22. (amended) The composition of claim 21 further comprising a colloidal dispersion system.

23. (amended) The composition of claim 21 wherein the antisense compound is an antisense oligonucleotide.

40. (amended) The antisense compound of claim 36 consisting of SEQ ID NO: 209.

49. (amended) A method of modulating interleukin-5 signal transduction in cells or tissues comprising contacting cells or tissues *in vitro* with the antisense compound of claim 1 so that interleukin-5 signal transduction is modulated.

50. (amended) A method of modulating the expression of human or murine interleukin-5 in human or murine cells or tissues

comprising contacting human or murine cells or tissues with the antisense compound of claim 3 so that expression of human or murine interleukin-5 is inhibited.

51. (amended) A method of modulating the expression of human or murine interleukin-5 receptor a in human or murine cells or tissues comprising contacting human or murine cells or tissues *in vitro* with the antisense compound of claim 33 so that expression of human or murine interleukin-5 receptor a is inhibited.

52. (amended) A method of altering the ratio of the isoforms of human or murine interleukin-5 receptor a in human or murine cells or tissues comprising contacting human or murine cells or tissues *in vitro* with the antisense compound of claim 33 so that the ratio of the human or murine interleukin-5 receptor a isoforms is altered.

53. (amended) A method of modulating the expression of human or murine interleukin-5 receptor a in human or murine cells or tissues comprising contacting human or murine cells or tissues *in vitro* with the antisense compound of claim 5 so that expression of human or murine interleukin-5 receptor a is inhibited.

54. (amended) A method of altering the ratio of the isoforms of human or murine interleukin-5 receptor a in human or murine

cells or tissues comprising contacting human or murine cells or tissues *in vitro* with the antisense compound of claim 31 so that the ratio of the human or murine interleukin-5 receptor a isoforms is altered.

67. (amended) The composition of claim 21 further comprising a chemotherapeutic agent for the treatment of asthma.

68. (amended) A composition comprising the antisense compound of claim 28 and a pharmaceutically acceptable carrier or diluent.

69. (amended) A composition comprising the antisense compound of claim 36 and a pharmaceutically acceptable carrier or diluent.

70. (amended) An *in vitro* diagnostic kit for detecting the expression level of a membrane versus a soluble form of IL-5 receptor a.

71. (amended) The *in vitro* diagnostic kit of claim 70 comprising the antisense compound of claim 33.

72. (amended) The *in vitro* diagnostic kit of claim 71 wherein the antisense compound is a peptide nucleic acid.

REMARKS

Claims 1-72 are pending in the instant application. Claims 1-72 have been rejected. Claims 3, 24-27 and 55-66 have been